Targeting EPHB2/ABL1 restores anti-tumor immunity in a preclinical model of ependymoma

被引：0
|
作者：
Ren, Jun
Amoozgar, Zohreh
Zhao, Yuhui
Lei, Pinji
Ho, William W.
Robergea, Sylvie
Huang, Peigen
Duda, Dan G.
Xu, Lei
Jain, Rakesh K.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2343
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042
    Kenkel, Justin A.
    Xiao, Fang
    Ho, Po Y.
    Nolin, Jess L.
    Gadkari, Rishali K.
    Torrez, Laughing Bear
    Omstead, David T.
    McEachin, Katelynn A.
    Ptacek, Jason
    Grgich, Rachel
    Pearson, Cecelia I.
    Chun, Stefan
    Kreder, Cindy L.
    Henning, Karla A.
    Kim, Han K.
    Xu, Lu
    Chapin, Steven J.
    Alonso, Michael N.
    Ackerman, Shelley E.
    CANCER RESEARCH, 2023, 83 (07)
  • [42] IDO1 INHIBITOR EPACADOSTAT PROMOTES ANTI-TUMOR IMMUNITY IN RADIATED COLORECTAL CANCER MODEL
    Chen, Baosheng
    Alvarado, David M.
    Santhanam, Srikanth
    Iticovici, Micah
    Thotala, Dinesh
    Ciorba, Matthew A.
    GASTROENTEROLOGY, 2018, 154 (06) : S874 - S874
  • [43] Preclinical study on the anti-tumor effect of H1 and H2 peptide.
    Hou, Wanru
    Hou, Yiling
    Ding, Xiang
    Liu, Xia
    Feng, Xue
    Yan, Yu
    Feng, Jiangnan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice
    Pan, Jiayi
    Zeng, Wuyi
    Jia, Jiangtao
    Shi, Yi
    Wang, Danni
    Dong, Jun
    Fang, Zixuan
    He, Jiashan
    Yang, Xinyu
    Zhang, Rong
    He, Menghua
    Huang, Maoping
    Fu, Bishi
    Zhong, Bei
    Liu, Hui
    VACCINES, 2022, 10 (07)
  • [45] ANTIBODY TARGETING NKG2D LIGANDS MICA/B TO UNLEASH ANTI-TUMOR IMMUNITY OF NK AND ILC1 CELLS
    Liu, Sizhe
    Smith, Tyler
    Zhu, Lisha
    Dhar, Payal
    Wu, Jennifer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1054 - A1054
  • [46] BL-M02D1, a novel Trop2-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation
    Zhang, Yong
    Wan, Weili
    Zhuo, Shi
    Chen, Lan
    Li, Gangrui
    Zhao, Shuwen
    Khalili, Jahan Salar
    Xiao, Sa
    Yan, Yongqi
    Shen, Xuejiao
    Zhu, Yi
    CANCER RESEARCH, 2023, 83 (07)
  • [47] Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2
    Stringer, Bradley
    Chouitar, Johara
    Cerbone, Jacqualine
    Fortin, Sarah
    Ainbinder, Alina
    Kysilovsky, Cassie
    Scott, Brittany
    Banerjee, Antara
    CANCER RESEARCH, 2024, 84 (07)
  • [48] Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation
    Chengyu Shi
    Ying Wang
    Minjie Wu
    Yu Chen
    Fangzhou Liu
    Zheyuan Shen
    Yiran Wang
    Shaofang Xie
    Yingying Shen
    Lingjie Sang
    Zhen Zhang
    Zerui Gao
    Luojia Yang
    Lei Qu
    Zuozhen Yang
    Xinyu He
    Yu Guo
    Chenghao Pan
    Jinxin Che
    Huaiqiang Ju
    Jian Liu
    Zhijian Cai
    Qingfeng Yan
    Luyang Yu
    Liangjing Wang
    Xiaowu Dong
    Pinglong Xu
    Jianzhong Shao
    Yang Liu
    Xu Li
    Wenqi Wang
    Ruhong Zhou
    Tianhua Zhou
    Aifu Lin
    Nature Communications, 15 (1)
  • [49] Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment
    Nachef, Marianna
    Ali, Alaa Kassim
    Almutairi, Saeedah Musaed
    Lee, Seung-Hwan
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [50] Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    Topalian, Suzanne L.
    Drake, Charles G.
    Pardoll, Drew M.
    CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) : 207 - 212
12345